Cerus Corporation revised revenue guidance for the year 2023. The company is adjusting its previously stated product revenue guidance range. The company expected full-year 2023 product revenue will be in the range of $160 million to $165 million, compared to its previous range of $165 million to $170 million, due to a temporary reduction in the U.S. platelet kit shelf life, a reduction in platelet collections in parts of Europe, and new Russia sanctions instituted during the quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.73 USD | -9.42% | +6.79% | -19.91% |
May. 02 | Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.91% | 320M | |
+10.39% | 126B | |
-6.86% | 10.96B | |
+2.52% | 8.97B | |
+38.96% | 5.56B | |
-17.50% | 4.99B | |
+8.36% | 3.44B | |
-8.84% | 2.8B | |
-7.52% | 2.18B | |
-3.00% | 2.16B |
- Stock Market
- Equities
- CERS Stock
- News Cerus Corporation
- Cerus Corporation Revises Revenue Guidance for the Year 2023